The world of biotech stocks got a new member today. Grail (NASDAQ:GRAL) has successfully completed its spinoff from industry leader Illumina (NASDAQ:ILMN). Previously, Grail had functioned as the company’s cancer-testing unit. However, after regulatory pressure, Illumina, known for its advances in the field of DNA sequencing, opted for the spinoff that would allow Grail to function as its own separate entity. Today, GRAL stock begins trading on the Nasdaq in what could be one of the summer’s hottest market ...